Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | SVP, Finance & CAO | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,860 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 19,000 · Balance 46,860 Row 2 · 2026-10-05 · Sale · Disposed 19,000 · Balance 27,860 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.92 · Expires 2032-08-08 | Direct | 74,068 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 19,000 · Balance 74,068 F2: Stock Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
F2: Stock Option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,322 | $73.08 | $169,701.05 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · nonDerivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,836 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.365. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 11,000 | $25.92 | $285,120.00 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · derivative · entry 7 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2024-02-28 F8 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 5,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,158 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. F2 · balance_after: Includes 457 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:34 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 627 | $51.00 | $31,977.00 |
DisclosureSEC source: 0001209191-23-048468 · doc4.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,301 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. F2 · balance_after: Includes 678 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 43,500 | $0.00 Strike: $41.67 | $0.00 |
DisclosureSEC source: 0001209191-23-015729 · doc4.xml · derivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Common Stock · 43,500 shares Expires 2033-03-01 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 7,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015729 · doc4.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.